Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease

Acta Orthopaedica

Volumn 80, Issue 2, 2009, Pages 201-204

  Lebel, Ehud ^a   Phillips, Mici ^b   Elstein, Deborah ^b   Zimran, Ari ^b   Itzchaki, Menachem ^a  

^a Department of Orthopaedic Surgery ^*  (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE NECROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; FEMUR HEAD; GAUCHER DISEASE; HIP ARTHROPLASTY; HUMAN; HUMERUS HEAD; JOINT DEGENERATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATIENT REFERRAL; PROGNOSIS; TENOTOMY; ARTHROPLASTY; FEMUR HEAD NECROSIS; FOLLOW UP; HUMERUS; JOINT; METHODOLOGY; MIDDLE AGED; ORTHOPEDIC SURGERY; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ARTHROPLASTY, REPLACEMENT; FEMALE; FEMUR HEAD NECROSIS; FOLLOW-UP STUDIES; GAUCHER DISEASE; HUMANS; HUMERUS; JOINTS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; OSTEONECROSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65449170095     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453670902930032     Document Type: Article

References (22)

1. Allen M J, Myer B J, Khokher A M, Rushton N, Cox T M. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10. QJM 1997; 90: 19-25.
2. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. Cytokines in Gaucher's disease. Eur Cytokine Netw 1999; 10: 205-210
3. Barton N W, Brady R O, Dambrosia J M, Di Bisceglie A M, Doppelt S H, Hill S C, Mankin H J, Murray G J, Parker R I, Argoff C E, et al. Replacement therapy for inherited enzyme deficiency: Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470
4. Beutler E, Grabowski G A. Gaucher disease. In: The metabolic and molecular bases of inherited diseases (eds. Scriver CR, Valle D, Beudet A, Sly W S). Vol III. McGraw-Hill. New York. 2001: 3635-3668
5. Charrow J, Dulisse B, Grabowski G A, Weinreb N J. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007; 71: 205-211
6. Cox T M. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis (Suppl 2) 2001; 24 :106-121
7. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 1996; 22: 104-111
8. Elstein D, Itzchaki M, Mankin H J. Skeletal involvement in Gaucher disease. In: Bailliere's clinical haematology (Zimran A ed). Harcourt Brace 1997; 10: 793-816.
9. Ficat R P. Treatment of avascular necrosis of the femoral head. Hip 1983: 279-295
10. Gardeniers J W M. Report of the Committee of Staging and Nomenclature. ARCO News Letter 1993; 5: 79-82.
11. Giraldo P, Solano V, Perez-Calvo J I, Giralt M, Rubio-Felix D, Spanish Group on Gaucher disease. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005; 14: 453-462
12. Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg (Am) 2006; 88: 2565-2572
13. Itzchaki M, Lebel E, Dweck A, Patlas M, Hadas-Halpern I, Zimran A, Elstein D. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004; 75 (6): 641-653 (Pubitemid 40018793)
14. McGrory B J, York S C, Iorio R, Macaulay W, Pelker R R, Parsley B S, Teeny S M. Current practices of AAHKS members in the treatment of adult osteonecrosis of the femoral head. J Bone Joint Surg (Am) 2007; 89: 1194-1204
15. Mont M A, Jones L C, Hungerford D S. Non-traumatic osteonecrosis of the femoral head: Ten years later. J Bone Joint Surg (Am) 2006; 88: 1117-1132
16. Mont M A, Marulanda G A, Seyler T M, Plate J F, Delanois R E. Core decompression and nonvascularized bone grafting for the treatment of early stage osteonecrosis of the femoral head. Instr Course Lect 2007; 56: 213-220
17. Neumayr L D, Aguilar C, Earles A N, Jergesen H E, Haberkern C M, Kammen B F, Nancarrow P A, Padua E, Milet M, Stulberg B N, Williams R A, Orringer E P, Graber N, Robertson S M, Vichinsky E P, National Osteonecrosis Trial in Sickle Cell Anemia Study Group. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg (Am) 2006; 88: 2573-2582
18. Poll L W, Maas M, Terk M R, Roca-Espiau M, Bembi B, Ciana G, Weinreb N J. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol (Suppl 1) 2002; 75: A25-36.
19. Rodrigue S W, Rosenthal D I, Barton N W, Zurakowski D, Mankin H J. Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop 1999; (362): 201-207
20. Seyler T M, Cui Q, Mihalko W M, Mont M A, Saleh K J. Advances in hip arthroplasty in the treatment of osteonecrosis. Instr Course Lect 2007; 56: 221-233
21. Steinberg M E, Larcom P G, Strafford B, Hosick W B, Corces A, Bands R E, Hartman K E. Core decompression with bone grafting for osteonecrosis of the femoral head. Clin Orthop 2001; (386): 71-78
22. Wenstrup R J, Bailey L, Grabowski G A, Moskovitz J, Oestreich A E, Wu W, Sun S. Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004; 104: 1253-1257